{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/corticosteroids-oral/how-up-to-date-is-this-topic/changes/","result":{"pageContext":{"chapter":{"id":"0863d2e0-89c0-59ea-8c15-e1b41fbd8d5d","slug":"changes","fullItemName":"Changes","depth":2,"htmlHeader":"<!-- begin field 2d562af2-c93c-4ed1-80bf-517aa069f2b0 --><h2>Changes</h2><!-- end field 2d562af2-c93c-4ed1-80bf-517aa069f2b0 -->","summary":null,"htmlStringContent":"<!-- begin item b602dcd9-befe-413a-944c-f75d7ecf7b5c --><!-- begin field 2ff3cdf0-9de4-4e4a-8c2b-96dddf32e765 --><p><strong>June 2020</strong> — minor update. The section on use of corticosteroids in pregnancy has been updated to clarify that available data do not suggest an increased risk of congenital malformations after first trimester exposure to oral corticosteroids.</p><p><strong>May 2020</strong> — reviewed. A literature search was conducted in April 2020 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of the topic.</p><!-- end field 2ff3cdf0-9de4-4e4a-8c2b-96dddf32e765 --><!-- end item b602dcd9-befe-413a-944c-f75d7ecf7b5c -->","topic":{"id":"2ddb5306-0521-5967-b3ad-e150e92dd71e","topicId":"72c594bc-4c91-4d24-acdb-dda9812ea656","topicName":"Corticosteroids - oral","slug":"corticosteroids-oral","lastRevised":"Last revised in June 2020","chapters":[{"id":"de758570-b276-5b9a-b679-243ca11b5b0b","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"5db581e9-0a76-58c3-9dc7-3d70e2258a58","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"083ae2c1-9fcd-56d9-9391-3b874be632d6","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"0863d2e0-89c0-59ea-8c15-e1b41fbd8d5d","slug":"changes","fullItemName":"Changes"},{"id":"1684d913-6ee4-5c81-b8f5-da290e6b10d2","slug":"update","fullItemName":"Update"}]},{"id":"e478b1f3-4d1b-57d5-879f-ad9022a2ec8f","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"d57df389-307f-59f5-a5e5-f223861afaba","slug":"goals","fullItemName":"Goals"},{"id":"70adac45-ee10-56f9-b88b-e75007cba584","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"fe005751-eb99-5634-a99d-041d841fd184","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"854fdd1a-f9cd-5b0f-95b0-ce2693d04cc8","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"03f7459a-9d10-5435-af19-3cb0a39f0a88","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"7c4a3b4a-3bfd-5b18-b16c-3350018754f3","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"c243f116-7197-5797-8dea-f74bd970f4d7","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"f776021e-e349-55a4-b655-4801dd7df8e5","slug":"definition","fullItemName":"Definition"},{"id":"241b5d44-7190-5d40-a453-c34255ed8c09","slug":"properties-of-corticosteroids","fullItemName":"Properties of corticosteroids"},{"id":"7cede1e7-70ca-59b2-a0b2-9da96d75e581","slug":"types-of-oral-corticosteroids","fullItemName":"Types of oral corticosteroids"},{"id":"00d48a00-08ac-5b67-a81d-79c587633318","slug":"equivalent-anti-inflammatory-doses","fullItemName":"Equivalent anti-inflammatory doses"}]},{"id":"2d718114-cca8-5be3-9f3b-cd6855079736","fullItemName":"Management","slug":"management","subChapters":[{"id":"84dd471a-9a74-5be7-b888-438a149d76de","slug":"corticosteroids","fullItemName":"Scenario: Corticosteroids"}]},{"id":"6e288e6d-366d-5598-be63-4261ab6000a9","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"cd130a7b-8ddf-543d-a4d2-e2b78c7ebe73","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"3b37794e-a5f1-56b1-a7e0-230805f097a3","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"e3c6ec19-1d84-510b-b44b-43ccb32f6b86","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"60803b59-24a4-5036-b82f-40d837e8e318","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"28cc6229-02b0-596c-b492-3dd868d5230b","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"7f63de84-1b36-5a2e-b3b3-626df702ff90","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"69d4244b-043f-55e0-80ac-64b46fe11694","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"083ae2c1-9fcd-56d9-9391-3b874be632d6","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"aefc2e06-f6f5-58e3-b48c-f5b269c350fd","slug":"previous-changes","fullItemName":"Previous changes","depth":3,"htmlHeader":"<!-- begin field 306f6a8e-9ab9-4f2d-839f-fa7f8961db32 --><h3>Previous changes</h3><!-- end field 306f6a8e-9ab9-4f2d-839f-fa7f8961db32 -->","summary":null,"htmlStringContent":"<!-- begin item 19c6ad1e-334f-41b4-a9f7-47be860115ab --><!-- begin field 5d0fc7e3-f6a1-4153-ad3b-dd5e95ce0cc4 --><p><strong>April 2020</strong> — minor update. Advice about using oral corticosteroids during the COVID-19 pandemic has been added in line with NICE rapid guidelines <em>COVID-19 rapid guideline: community-based care of patients with chronic obstructive pulmonary disease (COPD</em>) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-oral/references/\">NICE, 2020a</a>], <em>COVID-19 rapid guideline: dermatological conditions treated with drugs affecting the immune response</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-oral/references/\">NICE, 2020b</a>], and<em> COVID-19 rapid guideline: rheumatological autoimmune, inflammatory and metabolic bone disorders</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-oral/references/\">NICE, 2020c</a>]. </p><p><strong>November 2017</strong> — minor update. Information added on contraindications and cautions for use in people with systemic sclerosis as per updates to the manufacturers' summary of product characteristics. </p><p><strong>September 2017</strong> — minor update. Information added on ophthalmic adverse effects as per updates to the manufacturers' summary of product characteristics. </p><p><strong>December 2016</strong> — minor update. A recommendation to seek immediate medical attention if symptoms of adrenal insufficiency are experienced has been added to this topic [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-oral/references/\">ABPI, 2016a</a>].</p><p><strong>November 2016 </strong>— minor update. The contraindications section has been updated with the information that the administration of live or live, attenuated vaccines is contraindicated in patients receiving immunosuppressive doses of corticosteroids [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-oral/references/\">ABPI, 2016b</a>].</p><p><strong>June to August 2015 </strong>— reviewed. A literature search was conducted in June 2015 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last version of this topic. There have been no major changes to the recommendations.</p><p><strong>February 2014 </strong>— minor update. The text regarding how to minimize the risk of osteoporosis has been deleted and replaced with a link to the CKS topic <a class=\"topic-reference external-reference\" href=\"/topics/osteoporosis-prevention-of-fragility-fractures/\">Osteoporosis - prevention of fragility fractures</a>.</p><p><strong>April to August 2010 </strong>— this is a new CKS topic. The evidence-base has been reviewed in detail, and recommendations are clearly justified and transparently linked to the supporting evidence.</p><!-- end field 5d0fc7e3-f6a1-4153-ad3b-dd5e95ce0cc4 --><!-- end item 19c6ad1e-334f-41b4-a9f7-47be860115ab -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}